Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.58 |
| ▸ | POLR1A | O95602 | 1/20 | 0.53 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | HCN1 | O60741 | 1/20 | 0.48 |
| ▸ | BCL3 | P20749 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21348806 | 0.85 | DPP4 (0.57) | DPP4POLR1ADRD2 | |
| SCHEMBL13162932 | 0.82 | TP53 (0.53) | POLR1ADRD2HCN1 | |
| SCHEMBL19849442 | 0.81 | POLR1A (0.50) | DPP4POLR1ADRD2 | |
| SCHEMBL8049469 | 0.81 | CTSL (0.67) | DPP4 | |
| SCHEMBL18588481 | 0.78 | POLR1A (0.48) | DPP4POLR1ADRD2 | |
| SCHEMBL5949338 | 0.77 | KMT2A (0.47) | CHRM3 | |
| SCHEMBL29857237 | 0.77 | ALDH1A1 (0.56) | CHRM3 | |
| SCHEMBL21716773 | 0.77 | POLR1A (0.46) | DPP4POLR1ADRD2 | |
| SCHEMBL20356852 | 0.77 | POLR1A (0.46) | DPP4POLR1ADRD2 | |
| SCHEMBL11273600 | 0.76 | HTR4 (0.63) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10556898-B2 | Indazolyl-1,2,4-thiadiazolamines and related compounds for inhibition of Rho-associated protein kinase and the treatment of disease | LYCERA CORPORATION (US) | 2020-02-11 | — | — | US | disclosed |
| US-20190276447-A1 | INDAZOLYL-1,2,4-THIADIAZOLAMINES AND RELATED COMPOUNDS FOR INHIBITION OF RHO-ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE | LYCERA CORPORATION | 2019-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190276447-A1 | INDAZOLYL-1,2,4-THIADIAZOLAMINES AND RELATED COMPOUNDS FOR INHIBITION OF RHO-ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE | ROCK1, ROCK2, TNK2 | DPP4 3119/4885POLR1A 4816/4885CHRM3 1891/4885 |
| US-10556898-B2 | Indazolyl-1,2,4-thiadiazolamines and related compounds for inhibition of Rho-associated protein kinase and the treatment of disease | ROCK1, ROCK2, TNK2 | DPP4 3119/4885POLR1A 4816/4885CHRM3 1891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.